Hepatitis a vaccine inactivated - Biologic Drug Details

Summary for hepatitis a vaccine inactivated

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for hepatitis a vaccine inactivated

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis A Virus Vaccine
Chemical Structure	Hepatitis A Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hepatitis a vaccine inactivated Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hepatitis a vaccine inactivated Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for hepatitis a vaccine inactivated Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Inactivated Hepatitis A Vaccine

Last updated: February 22, 2026

What is the Market Size and Growth Potential for the Hepatitis A Vaccine?

The global hepatitis A vaccine market was valued at approximately $1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2030, reaching around $2 billion by 2030. Growth drivers include increasing hepatitis A incidence, expanding immunization programs, and emerging markets' rising healthcare expenditure.

How Does the Inactivated Hepatitis A Vaccine Fit Within the Broader Vaccine Market?

Inactivated hepatitis A vaccines represent a significant share of the hepatitis A segment, comprising nearly 70% of global vaccine sales based on current market data[1]. The remaining share consists of combination vaccines and live-attenuated formulations, which are less prevalent.

What Are the Key Factors Influencing Market Dynamics?

Demand Drivers

• Rising hepatitis A prevalence: An estimated 1.5 million cases annually worldwide.
• Immunization programs: Countries like the US, China, and Brazil have adopted widespread vaccination.
• Traveler vaccination: Increased global travel fuels demand.
• Aging populations: Older adults in endemic regions are at higher risk, boosting vaccine uptake.

Supply and Manufacturing Factors

• Leading manufacturers: GSK, Merck, and Sanofi produce inactivated hepatitis A vaccines.
• Manufacturing complexity: Inactivated vaccines require high bioprocessing standards, with lead times up to 18 months.
• Regulatory environment: Stringent approvals influence time-to-market and production costs.

Competitive Landscape

The market features a limited number of key players. GSK’s Havrix and Merck’s Vaqta are the dominant brands, with Sanofi’s Avaxim expanding presence in certain regions. Biosimilar entries are limited due to production complexities.

Pricing and Reimbursement

Average global vaccination costs range from $30 to $60 per dose. Reimbursement policies vary, with developed countries offering coverage through national immunization programs, while emerging markets often face out-of-pocket expenses.

What Are the Financial Trajectories and Investment Opportunities?

Revenue Projections

• Sales are expected to grow at a CAGR of 7.5%, reaching approximately $2 billion by 2030.
• The US accounts for nearly 35% of global sales, driven by CDC recommendations.
• Emerging markets, particularly in Asia, comprise about 30% of total sales, with rapid growth anticipated due to increased vaccination initiatives.

Investment Considerations

• Manufacturing investments are high, requiring advanced facilities and regulatory approvals.
• R&D expenditure: Companies are exploring combination vaccines to increase market share and improve compliance.
• Pricing strategies focus on affordability in emerging markets; premium pricing persists in developed nations.

Risks

• Regulatory delays may hinder market expansion.
• Competition from combination vaccines and potential new entrants pose long-term threats.
• Public health priorities shift, affecting immunization program funding.

How Do Regulatory and Policy Factors Shape the Market?

• WHO prequalification influences global acceptance and procurement.
• US CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine childhood vaccination, solidifying demand.
• Countries developing national immunization schedules have adopted hepatitis A vaccination, expanding market access.
• Regulatory agencies like FDA, EMA, and China’s NMPA impose standards that directly impact vaccine approval timelines and costs.

Summary Table: Market Size, Growth, and Key Players

Parameter	2022	2030 (Projected)
Market Value	$1.2 billion	~$2 billion
CAGR	—	7.5%
Major Markets	US, China, Brazil	US, Asia, Europe
Leading Manufacturers	GSK, Merck, Sanofi	Same
Share of Inactivated Vaccines	70%	Stable

Key Takeaways

• The hepatitis A vaccine market is growing steadily, driven primarily by immunization programs and traveler vaccination.
• Inactivated vaccines dominate the market owing to established safety and efficacy profiles.
• Market growth is constrained by manufacturing costs, regulatory hurdles, and competition from combination vaccines.
• Emerging markets present significant growth opportunities; affordability and infrastructure developments are critical.

FAQs

1. What is the main advantage of inactivated hepatitis A vaccines?

Inactivated hepatitis A vaccines offer a well-established safety profile, strong immunogenicity, and long-lasting immunity, often requiring only two doses for full protection.

2. How does the market size compare between developed and emerging economies?

Developed economies like the US and Europe account for approximately 50% of sales, whereas emerging markets, especially in Asia, are rapidly expanding and could reach 40% of total sales by 2030.

3. Are new formulations or combination vaccines affecting the market?

Yes. Combination vaccines that include hepatitis A components are entering the market, potentially replacing monovalent inactivated vaccines in certain regions but currently constitute a smaller market share.

4. What are the primary challenges facing manufacturers of hepatitis A vaccines?

Regulatory delays, high manufacturing costs, and competition from combination vaccines are leading challenges. Additionally, vaccine hesitancy in some regions may impact sales.

5. What is the likelihood of biosimilar entry into this market?

Low. The manufacturing complexity of inactivated hepatitis A vaccines raises barriers for biosimilar development, limiting entry to a few specialized producers.

---

References

[1] Markets and Markets. (2023). Hepatitis A vaccine market report.